Aspen Neuroscience
10835 Road to the Cure, Ste. 100
San Diego
California
92121
United States
Tel: (858) 263-1222
Website: https://aspenneuroscience.com/
Email: careers@aspenneuro.com
About Aspen Neuroscience
Headquartered in San Diego, Aspen Neuroscience, Inc. is a development stage, private biotechnology company focused on personalized cell therapies. We are developing autologous (the patient’s own) induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson’s disease (PD).
As a leading iPSC platform company, we combine stem cell biology with the latest artificial intelligence and genomic approaches to investigate patient-specific, restorative treatments. We have developed a best-in-class platform to create and characterize pluripotent-derived cell medicines, including in-house bioinformatics, manufacturing and QC.
Located in scenic Torrey Pines, Aspen features a culture in which employees are respected and rewarded for hard work, innovation, personal initiative, and collaboration. The leadership team is committed to attracting and retaining the highest caliber talent to develop meaningful therapies for patients in need.
12 articles about Aspen Neuroscience
-
Aspen Neuroscience Inks $40 Million Debt Deal with Silicon Valley Bank
12/21/2022
Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies including the first iPSC-derived autologous neuron replacement treatment for Parkinson's disease, has signed a $40 million credit facility with Silicon Valley Bank.
-
CMC Expert Kim Raineri Joins Aspen Neuroscience as Chief Technology Officer
10/19/2022
Aspen Neuroscience, Inc. announced that Kim Raineri has joined the company as Chief Technology Officer and as a member of the company's executive team.
-
Dr. Xiaokui Zhang to Present Aspen Neuroscience, Inc. at 2022 Cell & Gene Meeting on the Mesa
10/11/2022
This week Xiaokui Zhang , Ph.D., Chief Scientific Officer of Aspen Neuroscience, Inc. will present at the 2022 Cell & Gene Meeting on the Mesa Conference in Carlsbad, Calif.
-
NeuriTest™ Presented Publicly for the First Time at the International Society for Stem Cell Research Annual Meeting
6/22/2022
Aspen Neuroscience, Inc. Director of Bioinformatics, Roy Williams , Ph.D., presented NeuriTest™ for the first time publicly last week at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting in San Francisco, Calif.
-
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses. -
Aspen Neuroscience closed on a Series B funding round of $147.5 million. The company is focused on developing personalized cell replacements for Parkinson’s disease. -
Aspen Neuroscience Launches First Patient Screening Study for Planned Clinical Trial of Personalized Cell Replacement in Parkinson's Disease
4/11/2022
Aspen Neuroscience, Inc. announced that this month it will launch the first patient screening study of its kind.
-
Scientific Leader Xiaokui Zhang, Ph.D. Joins Aspen Neuroscience as Chief Scientific Officer
11/18/2021
Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson's disease, announced that Xiaokui Zhang, Ph.D., has joined the company as Chief Scientific Officer and as a member of the company's executive team.
-
Industry Veteran Kameel Farag Joins Aspen Neuroscience as Chief Financial Officer
11/9/2021
Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson's disease, announced that Kameel Farag has joined the company as Chief Financial Officer and as a member of the company's executive team.
-
Regulatory Affairs Expert Ana Sousa Joins Aspen Neuroscience as Senior Vice President
7/13/2021
Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson's disease, announced that Ana Sousa has joined the company as senior vice president of regulatory affairs and quality, and as a member of the company's executive team.
-
Aspen Neuroscience Announces Promotion of Andres Bratt-Leal, PhD, to Senior Vice President of Research & Development
5/5/2021
Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson's disease, announced that Andres Bratt-Leal, PhD, has been promoted to Senior Vice President of Research & Development.
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.